Human Stem Cell Derived Organoids – A New Frontier in Medicine
summary
TUM Center for Organoid Systems builds organoids from induced pluripotent stem cells to make functional tissues, including stem cell–derived beta cells already in clinical trials that render patients insulin-independent for over a year. Labs add a genetically encoded oxygen sensor that activates a protective circuit under hypoxia and load cells with nano probes for optical monitoring after transplant. For cancer, duct organoids on hydrogels and chips show that KRAS G12D turns ducts cancerous in four weeks, enabling gene editing, AI-driven drug screens and new biomarker discovery.
AI-written summary · about
chapters (12)
- 0:00Stem cell organoids intro
- 1:03What are organoids
- 2:26Stem cell types used
- 4:34Diabetes and beta cells
- 6:59Beta cells in trials
- 8:22Smart stem cells future
- 10:52AI in medicine evolution
- 11:34Pancreatic cancer research
- 13:41Duct organoids for cancer
- 15:47Early cancer in models
- 16:49Gene editing and AI
- 17:30Conclusion and outlook
